Company intelligence / Profile preview
Aclipse Therapeutics
KINGOFPRUSSIA/RADNORPAAREA, PENNSYLVANIA(PA), USAaclipsetherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Aclinical-stage biopharmaceutical company developing small-molecule therapeutics targeting severe neuromuscular and gastrointestinal diseases. Lead asset M107 enters US-based Phase II trials as the first potential disease-modifying therapy for gastroparesis; second asset M102 will enter human studies in ALS/MND with a novel dual-pathway mechanism.
- Therapeutic areas
- GastroenterologyNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
{"partner":
"ChongKunDangPharmaceuticalCorporation(CKD)","details":"Exclusiveworldwidelicense(excludingSouthKorea,
Indonesia,Vietnam)todevelopCKD'slobeglitazone(M107)forgastroparesisaswellasotherpotentialindications."}
Beyond the preview
Go deeper on Aclipse Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aclipse Therapeutics.